Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Open Label, Phase 3 Study to Compare the Efficacy and Safety of Lerodalcibep (LIB003) to Inclisiran in Patients at Very High or High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction

NCT05004675 is registered in ClinicalTrials.gov with LIB Therapeutics LLC as lead sponsor.

NCT NCT05004675
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05004675 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Open Label, Phase 3 Study to Compare the Efficacy and Safety of Lerodalcibep (LIB003) to Inclisiran in Patients at Very High or High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction
Lead sponsor
LIB Therapeutics LLC
Phase
Phase 3
Overall status
Completed
Start date
June 20, 2022
Completion date
October 15, 2024
Enrollment
166 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic ischemic disease, hypercholesterolemia